RecruitingPhase 2NCT05996627

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Studying Chronic graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fred Hutchinson Cancer Center
Principal Investigator
Stephanie Lee, MD, MPH
Fred Hutch/University of Washington Cancer Consortium
Intervention
Belumosudil(drug)
Enrollment
82 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (4)

Collaborators

Sanofi

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05996627 on ClinicalTrials.gov

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Chronic graft versus host disease

← Back to all trials